ArticleCase reports in ophthalmology
Treat-and-Extend Faricimab for Macular Neovascularization in Angioid Streaks: A Report of Two Cases.
Article in Case reports in ophthalmology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Angioid streaks (AS) are a rare retinal disorder that leads to progressive vision loss, particularly when complicated by macular neovascularization (MNV). Anti-vascular endothelial growth factor agents are the first-line treatment for MNV with AS; however, the optimal treatment strategy remains controversial. Herein, we present two cases of type 2 MNV secondary to AS treated with intravitreal faricimab (IVF), the first bispecific antibody, using a treat-and-extend (T&E) protocol over a 1-year follow-up. Case Presentations: Case 1: A 63-year-old male patient achieved dry macula after three monthly IVF injections, with visual acuity (VA) improving from 20/25 to 20/16. Subretinal fluid recurred 19 weeks after the loading phase, promoting treatment interval adjustment to 16 weeks. Fluid was subsequently controlled with two additional IVF injections with a 16-week interval. Over 1 year, VA was maintained at 20/16 with five IVF injections. Case 2: A 78-year-old female patient achieved dry macula with four monthly IVF injections, and VA improved from 20/32 to 20/16. The treatment interval was managed despite a recurrence at 16 weeks after the loading phase, leading to seven IVF injections over 1 year. VA remained stable at 20/16, although pre-existing focal macular atrophy slightly expanded. No subretinal fibrosis or severe ocular complications were observed in both cases. Conclusion: These findings support the efficacy and safety of IVF in the T&E regimen in managing AS-associated type 2 MNV, emphasizing the potential of dual-pathway inhibition for this challenging pathology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.